Silexion Therapeutics

What Silexion Therapeutics does

Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for cancers driven by KRAS mutations, with its lead program focused on locally advanced pancreatic cancer. The company's core platform combines small interfering RNA (siRNA) targeting mutant KRAS messenger RNA (specifically G12D and G12V, the most abundant KRAS mutations in pancreatic cancer) with a proprietary bioabsorbable PLG microparticle delivery system (30-70 µm) that enables sustained intratumoral release of siRNA over 2-3 months. SIL204, the second-generation lead candidate, is administered directly into pancreatic tumors via ultrasound-guided endoscopic ultrasound (EUS) and is currently advancing through Phase 2/3 clinical trials approved in both Israel and Germany. Preclinical data demonstrate up to 99.7% inhibition across eight KRAS mutations in four cancer types, and the first-generation LODER product previously showed median overall survival of 15.12 months in a Phase 1/2a trial.

Silexion is incorporated in the Cayman Islands (Silexion Therapeutics Ltd.), became publicly listed on Nasdaq under tickers SLXN and SLXNW via a August 2024 business combination with Moringa Acquisition Corp, and conducts operations primarily from Israel with GMP manufacturing handled by partner Catalent in Limoges, France. The company has no commercial revenue; it funds its development through periodic public equity offerings and warrant exercises, having raised over $18.6 million in aggregate gross proceeds during 2025 across multiple small financings. End customers, once commercialized, are anticipated to be oncology centers treating pancreatic and other KRAS-driven solid tumor patients.

The business model is a standard clinical-stage biotech structure: invest in R&D and clinical trials to reach regulatory approval, then commercialize directly or via partnerships, with potential future licensing royalties on the proprietary siRNA-PLG delivery platform. Silexion's go-to-market centers on investigator-led clinical trial execution at oncology centers in Israel and Germany, supplemented by investor relations activity at biotech conferences. Distribution of SIL204 is currently managed through CRO partner AMS Advanced Medical Services GmbH and manufacturing partner Catalent.

Name

Silexion Therapeutics

Legal name

Silexion Therapeutics Ltd.

Website

https://silexion.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Silexion Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies encapsulated in proprietary PLG microparticles to silence KRAS mutations, with lead candidate SIL204 in Phase 2/3 trials for locally advanced pancreatic cancer.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNAi therapeutics
• KRAS oncology drugs
• SiRNA cancer therapy
• Pancreatic cancer treatment
• Clinical-stage biotechnology

Headquarters

HQ city

Illinois City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: As a clinical-stage biotechnology company, Silexion does not currently generate revenue. The company is developing RNAi therapies for KRAS-driven cancers with SIL204 in Phase 2/3 clinical trials for locally advanced pancreatic cancer. Revenue would be generated upon successful FDA/EMA regulatory approvals and commercial launch of its therapeutic products.
2. Licensing Royalties: Potential future revenue from licensing its proprietary RNAi technology platform and delivery systems to other pharmaceutical companies for different cancer indications or therapeutic applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Silexion Therapeutics is a clinical-stage biotechnology company developing proprietary RNAi (RNA interference) therapies that silence KRAS oncogenic mutations driving cancer growth. Its lead product candidate SIL-204 encapsulates siRNA within PLG (poly lactic-co-glycolic acid) microparticles for sustained 2-3 month intratumoral release, targeting KRAS G12D and G12V mutations in solid tumors, with Phase 2/3 trials underway for locally advanced pancreatic cancer.

Product overview

Silexion Therapeutics is a clinical-stage oncology-focused biotechnology company developing proprietary RNAi-based therapies for KRAS-driven cancers. The company's platform technology consists of siRNA embedded in PLG microparticle delivery systems for treating solid tumors. The product portfolio includes LODER (first-generation siG12D-LODER), which completed Phase 1/2a trials and demonstrated positive efficacy results, and its optimized successor SIL-204 (second-generation), which features improved drug stability, tumor cell penetration, broader activity to additional KRAS mutations, and a 3-month extended-release profile. SIL-204 is currently advancing through Phase 2/3 clinical trials in locally advanced pancreatic cancer in Israel and Germany.

Differentiator

Problem solved

Functional benefit

Products and services

• LODER (Local Drug EluteR)

Quantifiable outcome

• Phase 2/3 trial approved in Israel and Germany for locally advanced pancreatic cancer
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• CatalentcoreTechnology or Integration · 13 May 2026Silexion partnered with Catalent for GMP clinical batch manufacturing of SIL204 at its facility in Limoges, France. Catalent is described as a global leading manufacturing partner and center of excellence for the production of SIL204 investigational therapy.
• Tel Aviv Sourasky Medical CentercoreStrategic or Co-development Partner · 24 March 2026Received approval from the Helsinki Ethics Committee at Tel Aviv Sourasky Medical Center for the planned Phase 2/3 trial in locally advanced pancreatic cancer. The medical center serves as a key clinical trial site.
• AMS Advanced Medical Services GmbHcoreImplementation/ SI/ Consulting Partner · 4 September 2025AMS was selected as CRO partner to support upcoming Phase 2/3 clinical trials for SIL204. The partnership follows preclinical data demonstrating up to 97% inhibition rates in pancreatic cancer cells and supports planned regulatory submissions to Israel Ministry of Health and EU.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Silence Therapeutics: Silence Therapeutics is a clinical-stage RNAi/siRNA company developing GalNAc-conjugated siRNA therapeutics across multiple disease areas. Comparable to Silexion as a peer siRNA-platform company, though Silence focuses on GalNAc liver-targeted delivery rather than Silexion's intratumoral PLG approach.
• Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals develops RNAi-based therapeutics using its proprietary TRiM platform for oncology and other diseases. Directly comparable to Silexion as an RNAi-focused company advancing nucleic acid therapeutics in oncology, though with broader targeting ligands and a larger pipeline.
• Wave Life Sciences: Wave Life Sciences develops stereopure nucleic acid-based therapeutics using siRNA and other oligonucleotide modalities. Directly comparable to Silexion as a peer clinical-stage nucleic-acid-therapy company using silencing approaches against genetic disease targets.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the pioneer and commercial leader in RNA interference therapeutics with multiple approved siRNA products. Broader-incumbent peer given its larger portfolio and infrastructure across multiple therapeutic areas including RNAi-based oncology programs.
• Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) company with multiple approved products and a deep clinical pipeline. Broad-incumbent peer in the oligonucleotide-therapeutics space, with a complementary but related antisense modality to Silexion's siRNA approach.
• BioNTech: BioNTech is a leading mRNA therapeutics company with a substantial oncology pipeline including KRAS-targeting cancer vaccine programs and RNA-based solid tumor therapies. Broad-incumbent peer operating in the RNA-based cancer therapeutics space with much greater scale and a broader modality portfolio.

Emerging players

• MiNA Therapeutics: MiNA Therapeutics is a clinical-stage RNA therapeutics company developing saRNA (small activating RNA) for cancer and liver disease. Emerging peer working in RNA-based oncology with a smaller pipeline than Silexion but a similar modality position.
• Revolution Medicines: Revolution Medicines develops targeted therapies focused on KRAS-driven cancers, including its broad pan-KRAS program RMC-6236 in lung and pancreatic cancers. Emerging peer directly competing with Silexion in the KRAS oncology space but using small-molecule inhibitors rather than RNAi.
• Erasca: Erasca is a clinical-stage precision oncology company developing multiple therapies against the RAS/MAPK pathway, including pan-KRAS and G12D-specific candidates. Emerging peer with overlapping target profile (KRAS) and similar clinical-stage development, but using small-molecule oncology approaches.
• Arcturus Therapeutics: Arcturus Therapeutics develops RNA-based therapeutics including siRNA and mRNA technologies, with oncology and rare disease programs. Emerging peer to Silexion as a smaller RNAi-platform company with overlapping modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Silexion Therapeutics